In a bittersweet decision for Biogen and Sage Therapeutics, the FDA approved the fast-acting drug zuranolone as the first tablet for postpartum depression on 04 August —but rejected the drug for major depressive disorder treatment. Zurzuvae is a neuroactive steroid that acts as a GABA-A receptor-positive allosteric modulator. Lower GABA levels in the body have been related to depression. Zuranolone, to be marketed as Zurzuvae in postpartum depression, is just the second medication for this indication and the first pill that may be used at home. The companies expect Zurzuvae to be commercially available for patients in the fourth quarter of this year, after its designa...
